SLC5A2 and hydrops fetalis: However, it should be emphasized that there were initially no differences between the analyzed groups in terms of pharmacological treatment, and more than half of the patients were initially taking SGLT2 inhibitors, despite the fact that this study was conducted in 2018–2023, and SGLT2 in HF therapy was recommended in the 2021 guidelines for HF.